Financial Personal
Galderma Reaffirms Its Leadership in Dermatology With Extensive Presence at EADV 2024
Late-breaking presentations will reveal important new data from the phase III OLYMPIA and ARCADIA trials, including durability and long-term efficacy of nemolizumab in prurigo nodularis and atopic dermatitis, respectively Galderma will also host a sy
ZUG, Switzerland -- Galderma (SWX:GALD), the pure-play dermatology category leader, announced today it will be showcasing updates from across its industry-leading dermatology portfolio at the 33rd European Academy of Dermatology and Venereology (EADV) congress taking place in Amsterdam, September 25-28, 2024, reinforcing its commitment to advancing dermatology for every skin story. In addition to presenting 30 abstracts with data on prurigo nodularis, atopic dermatitis, sensitive skin and acne, Galderma will host a series of events dedicated to addressing the real needs of patients and connecting with the dermatology community, including a symposium and several industry hub sessions and Meet the Experts sessions at the Galderma booth. Read More